Vaccination of boars with a GnRH vaccine (Improvac) eliminates boar taint and increases growth performance

• Published in: Journal of animal science 2001-10, Vol.79 (10), p.2524-2535
• Main Authors: Dunshea, F. R, Colantoni, C, Howard, K, McCauley, I, Jackson, P, Long, K. A, Lopaticki, S, Nugent, E. A, Simons, J. A, Walker, J, Hennessy, D. P
• Format: Article
• Language: English
• Subjects: Adipose Tissue - chemistry; Age Factors; Androstenes - analysis; Animal productions; Animals; Antibodies - blood; Biological and medical sciences; Bulbourethral Glands - physiology; Double-Blind Method; Fundamental and applied biological sciences. Psychology; Gonadotropin-Releasing Hormone - immunology; Hogs; Immunization - veterinary; Male; Meat - standards; Orchiectomy - veterinary; Organ Size; Physical growth; Sexual Maturation; Skatole - analysis; Swine - growth & development; Swine - metabolism; Terrestrial animal productions; Testis - physiology; Testosterone - blood; Vaccines; Vaccines - administration & dosage; Vaccines - immunology; Vertebrates
• ISSN: 0021-8812; 1525-3163; 0021-8812
• DOI: 10.2527/2001.79102524x

Peri- and postpubertal boars accumulate substances (e.g., androstenone and skatole) in their fatty tissue that are responsible for boar taint in pork. The objective of this study was to assess the efficacy of a GnRH vaccine, Improvac, in eliminating boar taint. Three hundred male (200 intact boars, 100 barrows) crossbred (Large White x Landrace) pigs were used in a 2 x 3 factorially arranged experiment. The respective factors were sex group (barrows, boars treated with placebo, or boars treated with Improvac) and slaughter age (23 or 26 wk). Vaccines were administered 8 and 4 wk before slaughter. All Improvac-treated pigs exhibited anti-GnRH titers. Testes and bulbo-urethral gland weights in treated pigs were reduced by approximately 50% (P < 0.001) and serum testosterone levels were below 2 ng/mL in the majority of treated boars (94 and 92% across both age groups at 2 and 4 wk, respectively). Boar taint, as assessed by the concentration of androstenone and skatole in s.c. fat, was suppressed to low or undetectable levels in 100% of Improvac-treated boars. No Improvac-treated pigs had significant concentrations of either androstenone (> 1.0 microg/g) or skatole (> 0.20 microg/g). In contrast, 49.5% of placebo-treated controls had significant androstenone and 10.8% had significant skatole levels, resulting in 10% of the control boars with high concentrations of both compounds. The mean concentrations of taint compounds in the Improvac-treated pigs were not significantly different from those in barrows. Improvac-treated boars grew more rapidly (P = 0.051 and < 0.001 for pigs slaughtered at 23 and 26 wk of age, respectively) than control boars over the 4 wk after the secondary vaccination, possibly because of reduced sexual and aggressive activities. Compared with barrows, Improvac-treated boars were leaner and had superior feed conversion efficiency. The vaccine was well tolerated by the pigs, and no observable site reactions could be detected at the time of slaughter. Vaccination of boars with Improvac allows production of heavy boars with improved meat quality through prevention and control of boar taint.